IMPACT BIOMEDICAL INC. (IBO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 20K 40K 60K Q4 '22: 50K Q1 '26: 39K Q2 '26: 35K Q4 '22 Q1 '26 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-30M -15M 0 15M 30M 45M Q3 '24: -3.7M Q4 '24: -28.8M Q1 '25: -29M Q2 '25: -29.5M Q3 '25: -29.3M Q4 '25: -4.3M Q1 '26: -5.6M Q2 '26: -5.1M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-60M -40M -20M 0 20M 40M 60M Q3 '24: 1.2M Q4 '24: -24.7M Q1 '25: -25M Q2 '25: -38.5M Q3 '25: -44.2M Q4 '25: -11.8M Q1 '26: -12.9M Q2 '26: 789K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '24: -2.3M Q4 '24: -2.9M Q1 '25: -3.1M Q2 '25: -3.4M Q3 '25: -3M Q4 '25: -1.9M Q1 '26: -1.7M Q2 '26: -508K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 40M 80M 120M Q1 '24: 10M Q2 '24: 10M Q3 '24: 11.5M Q1 '25: 12.1M Q2 '25: 12.2M Q3 '25: 12.2M Q1 '26: 107.8M Q2 '26: 107.8M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '22: -0.10 Q1 '23: -0.08 Q2 '23: -0.10 Q3 '23: -0.09 Q4 '23: -0.08 Q1 '24: -0.17 Q2 '24: -0.24 Q3 '25: -3.74 Q4 '22 Q1 '23 Q2 '23 Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.